Payment overview · 2025
General Payments
$260.18
13 reported records · 8 companies
Healthcare provider profile · identity verified
Ariel Martinez, MD
Allopathic & Osteopathic Physicians|Family Medicine · WATSONVILLE, CA · NPI 1831262880
Verified facts
What the public records show
CMS Open Payments records show Ariel Martinez, MD received $260.18 in general payments during 2025 across 13 reported records.
PFIZER INC. accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $101.19 | 38.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.32 | 13.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.38 | 10.9% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $28.00 | 10.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.85 | 9.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.32 | 7.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.92 | 5.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.20 | 3.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $260.18 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $125.04 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.38 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $28.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.20 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 82 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1019 | 299 |
| Metformin Hcl | Metformin Hcl | 598 | 180 |
| Baclofen | Baclofen | 499 | 178 |
| Pantoprazole Sodium | Pantoprazole Sodium | 435 | 126 |
| Gabapentin | Gabapentin | 368 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 347 | 111 |
| Losartan Potassium | Losartan Potassium | 345 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 334 | 106 |
| Glipizide Er | Glipizide | 329 | 97 |
| Carvedilol | Carvedilol | 300 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 285 | 124 |
| Lisinopril | Lisinopril | 273 | 80 |
| Omeprazole | Omeprazole | 267 | 88 |
| Jardiance | Empagliflozin | 257 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 249 | 81 |
| Mirtazapine | Mirtazapine | 210 | 60 |
| Buspirone Hcl | Buspirone Hcl | 192 | 51 |
| Tradjenta | Linagliptin | 192 | 42 |
| Glyxambi | Empagliflozin/Linagliptin | 187 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 50 |
| Montelukast Sodium | Montelukast Sodium | 167 | 51 |
| Tresiba Flextouch U-200 | Insulin Degludec | 157 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 148 | 47 |
| Levofloxacin | Levofloxacin | 145 | 107 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 143 | 111 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 134 | 39 |
| Ibuprofen | Ibuprofen | 120 | 50 |
| Meloxicam | Meloxicam | 114 | 44 |
| Ozempic | Semaglutide | 112 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 109 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 28 |
| Valsartan | Valsartan | 102 | 29 |
| Hydrocortisone | Hydrocortisone | 101 | 56 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 98 | 53 |
| Fluconazole | Fluconazole | 95 | 53 |
| Midodrine Hcl | Midodrine Hcl | 94 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 27 |
| Meclizine Hcl | Meclizine Hcl | 91 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 26 |
| Furosemide | Furosemide | 87 | 30 |
| Torsemide | Torsemide | 85 | 27 |
| Chlorthalidone | Chlorthalidone | 83 | 35 |
| Dutasteride | Dutasteride | 83 | 31 |
| Ketoconazole | Ketoconazole | 83 | 40 |
| Eliquis | Apixaban | 82 | 26 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 77 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 16 |
| Cefdinir | Cefdinir | 70 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 20 |
| Clotrimazole | Clotrimazole | 68 | 34 |
| Januvia | Sitagliptin Phosphate | 68 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 15 |
| Sertraline Hcl | Sertraline Hcl | 67 | 18 |
| Irbesartan | Irbesartan | 66 | 18 |
| Glipizide | Glipizide | 62 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 19 |
| Azithromycin | Azithromycin | 61 | 44 |
| Cephalexin | Cephalexin | 60 | 49 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 39 |
| Ventolin Hfa | Albuterol Sulfate | 57 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 16 |
| Fenofibrate | Fenofibrate,micronized | 54 | 20 |
| Nifedipine Er | Nifedipine | 54 | 14 |
| Azelastine Hcl | Azelastine Hcl | 53 | 17 |
| Memantine Hcl | Memantine Hcl | 51 | 12 |
| Telmisartan | Telmisartan | 51 | 19 |
| Terbinafine Hcl | Terbinafine Hcl | 51 | 18 |
| Ondansetron Odt | Ondansetron | 48 | 25 |
| Potassium Chloride | Potassium Chloride | 48 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 13 |
| Celecoxib | Celecoxib | 46 | 11 |
| Linzess | Linaclotide | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 15 |
| Famotidine | Famotidine | 43 | 14 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Levetiracetam | Levetiracetam | 41 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 39 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 39 | 11 |
| Trazodone Hcl | Trazodone Hcl | 38 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | 14 |
| Mupirocin | Mupirocin | 36 | 32 |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 35 | 31 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Sucralfate | Sucralfate | 34 | 12 |
| Metronidazole | Metronidazole | 33 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Memantine Hcl Er | Memantine Hcl | 31 | 11 |
| Dexamethasone | Dexamethasone | 30 | 26 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Colchicine | Colchicine | 28 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 19 |
| Atenolol | Atenolol | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | 15 |
| Lidocaine | Lidocaine | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | 12 |
| Tramadol Hcl | Tramadol Hcl | 26 | 11 |
| Finasteride | Finasteride | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 14 |
| Topiramate | Topiramate | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Tobramycin | Tobramycin | 15 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Imiquimod | Imiquimod | 14 | 11 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fosinopril-Hydrochlorothiazide | Fosinopril/Hydrochlorothiazide | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $260.18 · 13 records | PFIZER INC. | Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, Hizentra, Kerendia, TRELEGY ELLIPTA, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error